國家衛生研究院 NHRI:
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 906885      Online Users : 891
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version

    Collection

    Periodical Articles [327/330]
    Books/Book Section [1/1]
    Conference Papers/Meeting Abstract [115/179]

    Community Statistics


    Item counts issued in 3 years:74(14.51%)
    Items With Fulltext:443(86.86%)

    Download counts of the item
    Download times greater than 0:443(100.00%)
    Download times greater than 100:426(96.16%)
    Total Bitstream Download Counts:178127(3.32%)

    Last Update: 2024-12-01 08:26

    Top Upload

    Loading...

    Top Download

    Loading...

    RSS Feed RSS Feed
    Jump to a point in the index:
    Or type in a year:
    Ordering With Most Recent First Show Oldest First

    Showing items 1-25 of 510. (21 Page(s) Totally)
    1 2 3 4 5 6 7 8 9 10 > >>
    View [10|25|50] records per page

    DateTitleRelation
    2024-10 A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study Oncologist. 2024 Oct 3;29(10):e1396-e1405.
    2024-08-20 Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri Gastric Cancer. 2024 Aug 20;Article in Press.
    2024-08-06 Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer ESMO Open. 2024 Aug 06;9(8):Article number 103647.
    2024-08 Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study Lancet. Gastroenterology and Hepatology. 2024 Aug;9(8):694-704.
    2024-07-11 Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study BMC Cancer. 2024 Jul 11;24:Article number 828.
    2024-06-21 Topiramate suppresses peri-infarct spreading depolarization and improves outcomes in a rat model of photothrombotic stroke iScience. 2024 Jun 21;27(6):Article number 110033.
    2024-06-17 Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer Future Oncology. 2024 Jun 17;Article in Press.
    2024-05 Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer Pancreatology. 2024 May;24(3):600-607.
    2024-03 RNF43 inactivation enhances the B-RAF/MEK signaling and greates a combinatory therapeutic target in cancer cells Advanced Science. 2024 Mar;11(12):Article number e2304820.
    2024-02-20 Chromatin remodeling-related PRDM1 increases stomach cancer proliferation and is counteracted by bromodomain inhibitor Journal of Personalized Medicine. 2024 Feb 20;14(3):Article number 224.
    2024-02-15 Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway American Journal of Cancer Research. 2024 Feb 15;14(2):448-466.
    2024-02-13 Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan Journal of Biomedical Science. 2024 Feb 13;31:Article number 21.
    2024-02-01 Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression Liver Cancer. 2024 Feb 01;Article in Press.
    2023-11-22 The prognosis performance of a neutrophil- and lymphocyte-associated gene mutation score in a head and neck cancer cohort Biomedicines. 2023 Nov 22;11(12):Article number 120209.
    2023-11 Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer Future Oncology. 2023 Nov;19(34):2277-2289.
    2023-11 Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390.
    2023-11 Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis Annals of Oncology. 2023 Nov;34(Suppl. 4):S1536-S1537.
    2023-10 The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: A noninterventional, uncontrolled multicenter study British Journal of Cancer. 2023 Oct;129(6):947-955.
    2023-10 Risk of type 2 diabetes mellitus and hyperlipidemia in patients with chronic myeloid leukemia initiating tyrosine kinase inhibitors: A nationwide cohort study Pharmacoepidemiology and Drug Safety. 2023 Oct;32(Suppl. S1):575.
    2023-09-01 The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study International Journal of Surgery. 2023 Sep 1;109(9):2614-2623.
    2023-09 Carbohydrate antigen 19-9 response to initial adjuvant chemotherapy predicts survival and failure pattern of resected pancreatic adenocarcinoma but not which patients are suited for additional adjuvant chemoradiation therapy: From a prospective randomized study International Journal of Radiation Oncology Biology Physics. 2023 Sep 1;117(1):74-86.
    2023-08-15 Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination American Journal of Cancer Research. 2023 Aug 15;13(8):3417-3432.
    2023-08 The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study Cancer Medicine. 2023 Aug;12(16):16906-16917.
    2023-07 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462 Annals of Oncology. 2023 Jul;34(7):633.
    2023-06 Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors Journal of Clinical Oncology. 2023 Jun;41(16, Suppl.):Meeting Abstract 3148.

    Showing items 1-25 of 510. (21 Page(s) Totally)
    1 2 3 4 5 6 7 8 9 10 > >>
    View [10|25|50] records per page

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback